Cited by 164Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

FGF21-based pharmacotherapy – potential utility for metabolic disorders

Gimeno, Ruth E., Moller, David E.·2014·Trends in Endocrinology & Metabolism

Abstract

Currently available therapies for diabetes or obesity produce modest efficacy and are usually used in combination with agents targeting cardiovascular risk factors. Fibroblast growth factor 21 (FGF21) is a circulating protein with pleiotropic metabolic actions; pharmacological doses of FGF21 produce anti-diabetic, lipid-lowering, and weight-reducing effects in rodents. Several potential benefits have translated to non-human primates and obese humans with type 2 diabetes (T2D). Accumulating results point to a specific receptor complex and actions in adipose tissue, liver, and brain; several pathways lead to enhanced fatty acid oxidation, increased insulin sensitivity, and augmented energy expenditure. A range of strategies are being explored to derive potent, safe, and convenient therapies which could potentially represent novel approaches to prevent and treat a variety of metabolic disorders.

Integrity signals

Registry

Crossref · 10.1016/j.tem.2014.03.001

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gimeno, R. E., & Moller, D. E.
Affiliations
Eli Lilly (United States) (US)
Corresponding author
  • Gimeno, Ruth E.
  • Moller, David E.
Venue
Trends in Endocrinology & Metabolism
Publisher
Elsevier BV
Published
2014-06
Volume
25
Issue
6
Pages
303-311
ISSN
1043-2760 (ISSN-L)
OpenAlex
W2038863889
Cited by
163
References
82
Citations by year
2026: 4 · 2025: 4 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 14 · 2020: 15 · 2019: 14 · 2018: 13 · 2017: 16 · 2016: 36 · 2015: 21 · 2014: 3
FWCI
2.39
Type
journal article
Language
en
Open access
closed
Locations
  • Trends in Endocrinology and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
FGF21, type 2 diabetes, obesity, metabolic disorders, antidiabetic therapy, hypolipidemic effect, weight loss, insulin sensitivity, fatty acid oxidation, energy expenditure, adipose tissue, liver, brain, non-human primates
MeSH terms
Animals, Diabetes Mellitus, Type 2, Energy Metabolism, Fibroblast Growth Factors, Humans, Metabolic Diseases, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review